Sunshine Pharma (06887) has announced its interim results for the six months ended June 30, 2026. The group recorded revenue of RMB 1.075 billion and a gross profit of RMB 578 million, while reporting a loss attributable to equity shareholders of the company of RMB 604 million, translating to a loss per share of RMB 1.09.

Looking ahead, the company intends to allocate its robust operating cash flow towards research and development activities. This strategic move aims to significantly enhance capital utilization efficiency and provide ample support for its drug development pipeline. Leveraging its financial strength, the company will continue to reinforce its proprietary R&D platform, with a commitment to delivering superior medical solutions and affordable pharmaceutical products to patients, focusing on drugs with substantial market potential in their respective therapeutic areas.

The company's strong R&D capabilities are expected to continually enrich its future commercial product portfolio, laying a solid foundation for sustainable business growth and long-term value creation. Management plans to streamline decision-making processes to boost operational agility, enabling swift responses to market shifts and various challenges. This includes flexible adjustments to sales channels for different drugs and advancing a dual-track globalization strategy covering both market expansion and technological development.

Additionally, the company will accelerate the consolidation of its mid-and-back-office functions, promoting the implementation of an integrated, fully digitalized back-office system. This encompasses finance, R&D, sales, procurement, inventory, administrative office systems, and digital infrastructure. Furthermore, Sunshine Pharma will optimize and adjust its previous connected transaction arrangements, aiming to improve decision-making and capital allocation efficiency while reducing governance costs.